[Candidiasis].

Abstract

Diabetes mellitus (DM) has been considered to predispose to candidiasis. While poor glycemic control increases the risk of superficial candidiasis (especially oral candidiasis), invasive candidiasis is not related to DM. Invasive candidiasis is diagnosed by combination of clinical manifestation, laboratory findings and isolation of Candida spp. Strategy of treatment for invasive candidiasis is consist of prophylactic, empiric and targeted therapy. MCFG, FLCZ and AMPH-B are recommended as first line drugs for invasive candidiasis, and L-AMB, VRCZ, ITCZ are considered as alternative drugs in Japanese guideline.

• Authors: Yoshifumi Imamura, Koichi Izumikawa, Shigeru Kohno
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 66 Issue 12 Pg. 2341-4 (Dec 2008) ISSN: 0047-1852 [Print] Japan
• PMID: 19069102 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents
• Antigens, Fungal
• Biomarkers
• Echinocandins
• Lipopeptides
• Proteoglycans
• beta-Glucans
• polysaccharide-K
• Amphotericin B
• Fluconazole
• Micafungin

Topics

• Amphotericin B (administration & dosage)
• Antifungal Agents (administration & dosage)
• Antigens, Fungal (blood)
• Biomarkers (blood)
• Candida (immunology, isolation & purification)
• Candidiasis (diagnosis, drug therapy, prevention & control)
• Diabetes Complications
• Echinocandins (administration & dosage)
• Fluconazole (administration & dosage)
• Humans
• Lipopeptides (administration & dosage)
• Micafungin
• Proteoglycans
• beta-Glucans (blood)